ZA200803940B - [4-(Benzo[B]thiophen-2-yl) pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases - Google Patents
[4-(Benzo[B]thiophen-2-yl) pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseasesInfo
- Publication number
- ZA200803940B ZA200803940B ZA200803940A ZA200803940A ZA200803940B ZA 200803940 B ZA200803940 B ZA 200803940B ZA 200803940 A ZA200803940 A ZA 200803940A ZA 200803940 A ZA200803940 A ZA 200803940A ZA 200803940 B ZA200803940 B ZA 200803940B
- Authority
- ZA
- South Africa
- Prior art keywords
- ikk
- thiophen
- pyrimidin
- benzo
- cancer
- Prior art date
Links
- VDEYQSOFDSCWMV-UHFFFAOYSA-N 4-(1-benzothiophen-2-yl)pyrimidin-2-amine Chemical class NC1=NC=CC(C=2SC3=CC=CC=C3C=2)=N1 VDEYQSOFDSCWMV-UHFFFAOYSA-N 0.000 title 1
- 102000001284 I-kappa-B kinase Human genes 0.000 title 1
- 108060006678 I-kappa-B kinase Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73809705P | 2005-11-18 | 2005-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200803940B true ZA200803940B (en) | 2009-09-30 |
Family
ID=38345605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200803940A ZA200803940B (en) | 2005-11-18 | 2008-05-08 | [4-(Benzo[B]thiophen-2-yl) pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7547691B2 (enExample) |
| EP (1) | EP1989200B1 (enExample) |
| JP (1) | JP2009516697A (enExample) |
| KR (1) | KR100990771B1 (enExample) |
| CN (1) | CN101309918B (enExample) |
| AR (1) | AR057911A1 (enExample) |
| AT (1) | ATE437873T1 (enExample) |
| AU (1) | AU2006337626B2 (enExample) |
| BR (1) | BRPI0618245A2 (enExample) |
| CA (1) | CA2629336A1 (enExample) |
| CR (1) | CR9947A (enExample) |
| DE (1) | DE602006008187D1 (enExample) |
| DK (1) | DK1989200T3 (enExample) |
| EA (1) | EA014426B1 (enExample) |
| EC (1) | ECSP088456A (enExample) |
| ES (1) | ES2329085T3 (enExample) |
| IL (1) | IL190489A0 (enExample) |
| MA (1) | MA30053B1 (enExample) |
| NO (1) | NO20082594L (enExample) |
| PE (1) | PE20070833A1 (enExample) |
| PL (1) | PL1989200T3 (enExample) |
| PT (1) | PT1989200E (enExample) |
| SI (1) | SI1989200T1 (enExample) |
| TN (1) | TNSN08227A1 (enExample) |
| TW (1) | TW200800201A (enExample) |
| WO (1) | WO2007092095A2 (enExample) |
| ZA (1) | ZA200803940B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007117399A2 (en) | 2006-03-31 | 2007-10-18 | Janssen Pharmaceutica N.V. | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor |
| CA2658764A1 (en) * | 2006-07-20 | 2008-01-24 | Mehmet Kahraman | Benzothiophene inhibitors of rho kinase |
| RS51526B (sr) * | 2006-12-21 | 2011-06-30 | Eli Lilly & Company | Jedinjenja imidazolidinonil aminopirimidina za lečenje kancera |
| CA2671738A1 (en) * | 2006-12-21 | 2008-06-26 | Eli Lilly And Company | Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer |
| MX2009012233A (es) | 2007-05-16 | 2009-12-01 | Lilly Co Eli | Compuestos de triazolil aminopirimidina. |
| CA2691997A1 (en) | 2007-05-16 | 2008-11-27 | Eli Lilly And Company | Triazolyl aminopyrimidine compounds |
| EP2924025A1 (en) * | 2008-06-30 | 2015-09-30 | Janssen Pharmaceutica NV | Substituted pyrimidine derivatives |
| US9371311B2 (en) | 2008-06-30 | 2016-06-21 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidine derivatives |
| KR101123178B1 (ko) * | 2009-04-09 | 2012-06-13 | (주)에스메디 | 2-아릴벤조싸이오펜 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물 |
| BR112012003661A2 (pt) | 2009-08-19 | 2017-04-25 | Ambit Biosciences Corp | "compostos de biarila e métodos de uso dos mesmos." |
| KR20130069641A (ko) | 2010-04-27 | 2013-06-26 | 허치슨 메디파르마 리미티드 | 피리미디닐 인돌 화합물 |
| US20140194383A1 (en) | 2011-04-07 | 2014-07-10 | Cornell University | Monomers capable of dimerizing in an aqueous solution, and methods of using same |
| US9245773B2 (en) | 2011-09-02 | 2016-01-26 | Taiwan Semiconductor Manufacturing Company, Ltd. | Semiconductor device packaging methods and structures thereof |
| CN103159742B (zh) * | 2011-12-16 | 2015-08-12 | 北京韩美药品有限公司 | 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用 |
| AU2013216935C1 (en) | 2012-02-08 | 2017-12-14 | John Emmerson Campbell | Heteroaryl compounds and methods of use thereof |
| US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
| JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| CN105085434B (zh) * | 2014-05-09 | 2018-02-09 | 上海特化医药科技有限公司 | 硫乙拉嗪或其中间体的制备方法 |
| WO2017076888A1 (en) | 2015-11-03 | 2017-05-11 | Janssen Pharmaceutica Nv | 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides and methods of making the same |
| MX2019000982A (es) | 2016-07-29 | 2019-07-04 | Sunovion Pharmaceuticals Inc | Compuestos y composiciones y usos de los mismos. |
| EA201990400A1 (ru) | 2016-07-29 | 2019-07-31 | Суновион Фармасьютикалз, Инк. | Соединения и композиции и их применение |
| WO2018140513A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
| US11358959B2 (en) * | 2017-01-26 | 2022-06-14 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| CN110869358A (zh) | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | Kras的共价抑制剂 |
| CN110831933A (zh) | 2017-05-25 | 2020-02-21 | 亚瑞克西斯制药公司 | 喹唑啉衍生物作为突变kras、hras或nras的调节剂 |
| JP7191085B2 (ja) | 2017-08-02 | 2022-12-16 | サノビオン ファーマシューティカルズ インク | イソクロマン化合物およびその使用 |
| BR112021001709A2 (pt) | 2018-08-01 | 2021-05-04 | Araxes Pharma Llc | compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer |
| CN113784755B (zh) | 2019-03-14 | 2024-05-10 | 赛诺维信制药公司 | 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物 |
| WO2026086911A1 (en) * | 2024-10-24 | 2026-04-30 | Fujian Haixi Pharmaceuticals Co., Ltd. | Tyrosine kinase inhibitors and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989011279A1 (en) * | 1988-05-16 | 1989-11-30 | Georgia State University Foundation, Inc. | Nucleic acid interacting unfused heteropolycyclic compounds |
| GB0308466D0 (en) * | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
| JP4932735B2 (ja) * | 2004-12-17 | 2012-05-16 | アムジエン・インコーポレーテツド | アミノピリミジン化合物および使用方法 |
-
2006
- 2006-10-23 TW TW095139053A patent/TW200800201A/zh unknown
- 2006-11-15 PL PL06850430T patent/PL1989200T3/pl unknown
- 2006-11-15 BR BRPI0618245-3A patent/BRPI0618245A2/pt not_active IP Right Cessation
- 2006-11-15 CN CN2006800428126A patent/CN101309918B/zh not_active Expired - Fee Related
- 2006-11-15 JP JP2008541463A patent/JP2009516697A/ja not_active Ceased
- 2006-11-15 CA CA002629336A patent/CA2629336A1/en not_active Abandoned
- 2006-11-15 EA EA200801362A patent/EA014426B1/ru not_active IP Right Cessation
- 2006-11-15 AU AU2006337626A patent/AU2006337626B2/en not_active Ceased
- 2006-11-15 PT PT06850430T patent/PT1989200E/pt unknown
- 2006-11-15 KR KR1020087011830A patent/KR100990771B1/ko not_active Expired - Fee Related
- 2006-11-15 EP EP06850430A patent/EP1989200B1/en active Active
- 2006-11-15 SI SI200630446T patent/SI1989200T1/sl unknown
- 2006-11-15 US US12/093,024 patent/US7547691B2/en not_active Expired - Fee Related
- 2006-11-15 PE PE2006001456A patent/PE20070833A1/es not_active Application Discontinuation
- 2006-11-15 DE DE602006008187T patent/DE602006008187D1/de active Active
- 2006-11-15 WO PCT/US2006/060911 patent/WO2007092095A2/en not_active Ceased
- 2006-11-15 DK DK06850430T patent/DK1989200T3/da active
- 2006-11-15 ES ES06850430T patent/ES2329085T3/es active Active
- 2006-11-15 AT AT06850430T patent/ATE437873T1/de active
- 2006-11-17 AR ARP060105065A patent/AR057911A1/es unknown
-
2008
- 2008-03-27 IL IL190489A patent/IL190489A0/en unknown
- 2008-04-29 CR CR9947A patent/CR9947A/es not_active Application Discontinuation
- 2008-05-08 ZA ZA200803940A patent/ZA200803940B/xx unknown
- 2008-05-16 EC EC2008008456A patent/ECSP088456A/es unknown
- 2008-05-16 TN TNP2008000227A patent/TNSN08227A1/en unknown
- 2008-06-10 NO NO20082594A patent/NO20082594L/no not_active Application Discontinuation
- 2008-06-13 MA MA31035A patent/MA30053B1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL190489A0 (en) | [4-(benzo[b] thiophen-2-yl) pyrimidin-2yl]-amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases | |
| AP2007004004A0 (en) | Pyrrolidyl derivatives of heteroaromatic compoundsas phosphodiesterase inhibitors | |
| IL195731A0 (en) | Pyrimidine derivatives useful in the treatment of cancer | |
| IL194425A0 (en) | N-oxides of heterocyclic substituted bisarylureas for treating kinase-mediated diseases | |
| ZA201000075B (en) | Purin derivatives for use in the treatment of fab-related diseases | |
| SI2220030T1 (sl) | Derivati 4-(p-kuinonil)-2-hidroksibutanamida za zdravljenje mitohondrijskih bolezni | |
| IL196998A0 (en) | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders | |
| NZ602041A (en) | Heterocyclic inhibitors of histamine receptors for the treatment of disease | |
| IL193230A (en) | Use of benzoxoborol derivatives in the preparation of drugs for the treatment of inflammatory diseases | |
| MX2009006706A (es) | Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos. | |
| IL184934A0 (en) | 4-oxoquinazoline-3-yl-benzamide derivatives for the treatment of cytokine diseases | |
| WO2009011850A3 (en) | Novel therapeutic compounds | |
| IL210055A0 (en) | Thiophene or thiazole derivatives and their use as pi3k inhibitors | |
| IL212716A0 (en) | Thieno [3,2-c] pyridine derivatives as kinase inhibitors for use in the treatment of cancer | |
| IL194948A0 (en) | 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial | |
| ZA200708591B (en) | Pyrimidine derivatives for treatment of hyperproliferative disorders | |
| IL187739A0 (en) | New 2-azetidinone derivatives for the treatment of hyperlipidaemic diseases | |
| IL197504A (en) | Isoserine derivatives as coagulation factor ixa inhibitors | |
| IL179210A0 (en) | Heterocyclic derivatives for treatment of hyperlipidemia and related diseases | |
| SI1773787T1 (sl) | Postopek za pripravo 3-fenil(tio)uracilov in ditiouracilov | |
| ZA200901015B (en) | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders | |
| HK1123805A (en) | [4-(benzo[b]thiophen-2-yl)-pyrimidin-2-yl]-amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases | |
| IL178444A0 (en) | 6-substituted pyridoindolone derivatives production and therapeutic use thereof | |
| ZA200810524B (en) | Pyrimidine derivatives useful in the treatment of cancer | |
| GB0425054D0 (en) | Formamide derivatives for the treatment of diseases |